Company Filing History:
Years Active: 2019
Title: Innovator Snehal Ameet Gadve: Advancements in Pharmacology
Introduction
Snehal Ameet Gadve, an inventive mind hailing from Maharashtra, India, is recognized for his significant contributions to the field of pharmacology. With a focused expertise in pharmaceutical formulations, he has developed a patent that reflects his innovative approach to drug delivery systems.
Latest Patents
Gadve holds a patent for "Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters." This invention describes a timed-release pharmaceutical composition of donepezil that showcases an in vitro dissolution profile. Specifically, when tested in a Paddle dissolution apparatus at 50 rpm in 900 ml of 6.8 buffer at 37°C, less than about 20% w/w of donepezil is released in 3 to 6 hours, and more than 90% w/w of donepezil is released after 12 hours. This innovation is pivotal for enhancing the therapeutic efficacy of donepezil in clinical settings.
Career Highlights
Currently, Snehal Ameet Gadve is affiliated with Lupin, Inc., a leading global pharmaceutical company known for its commitment to providing high-quality medicines. His work at Lupin involves not only the development of innovative drug formulations but also the continuous advancement of pharmaceutical technologies.
Collaborations
Throughout his career, Gadve has collaborated with notable professionals in his field, including Dhananjay Sadashiv Bakhle and Chirag Anilkumar Shah. These collaborations indicate his commitment to teamwork and fostering innovation through shared expertise and knowledge.
Conclusion
Snehal Ameet Gadve exemplifies the role of a modern inventor in the pharmaceutical industry. His patent is a testament to his ingenuity and dedication to improving patient care through innovative drug formulations. As he continues his work at Lupin, the future holds promise for further contributions to pharmacological science and therapeutic advancements.